Medication Monitor

Generic Name (Trade Name—Company)
February 1, 2011

Meningococcal [groups A, C, Y, and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine

OK'd for children 2 to 10 years old


Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in children 2 to 10 years of age

Approval was based on Phase III trial data involving 5,297 children 2 to 10 years of age proving the safety and immunogenicity of Menveo compared with the other currently U.S.-licensed ACW-135Y meningococcal conjugate vaccine. The vaccine was initially approved in 2010 for active immunization in adolescents and adults 11 to 55 years of age.